Akoya Biosciences, The Spatial Biology Company™, offers the most comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications. The company has two industry-leading platforms that empower investigators and researchers to gain a deeper understanding of complex diseases such as cancer, and autoimmune or neurological disorders. The CODEX® system is the only benchtop platform that can efficiently quantify more than 40 protein biomarkers and is ideally suited for biomarker discovery. The Phenoptics™ platform is the only end-to-end multiplexed immunofluorescence solution with the robustness and high throughput necessary for translational research and clinical trials.
Selected Press Releases
Akoya Biosciences Raises $50 Million in New Financing
Investment funds significant expansion of Akoya | December 5, 2019
Study Shows Spatial Biology Is Essential for Predicting Response to Immuno-Oncology Treatment
Leading immuno-oncology labs publish study in JAMA Oncology | July 18, 2019
Akoya Biosciences Acquires Phenoptics Portfolio from PerkinElmer
Akoya Biosciences’ acquisition of PerkinElmer’s Phenoptics portfolio | October 31, 2018
If you have further questions or images please reach us here.
Media Contact for Akoya: